US Food and Drug Administration approval of Gardasil (human papillomavirus vaccine) has been widened to include prevention of anal cancer and associated precancerous lesions, the agency said in a recent news release.

Human papillomavirus (HPV) is associated with about 90% of the estimated 5,300 cases of anal cancer diagnosed in the United States each year, the FDA said, citing statistics from the American Cancer Society. More women are diagnosed than men.

The latest approval for Gardasil covers people aged nine to 26. The vaccine was previously approved for the same age group to prevent cervical, vulvar and vaginal cancers in females, and for genital warts among both sexes.

Gardasil won't prevent development of anal precancerous lesions already present at the time of vaccination from turning into cancer, the FDA said.

The most common adverse reactions to the vaccine include fainting, injection-site pain, headache, nausea and fever.

Want to Keep Reading?

Continue reading with a Health Confidential membership.

Sign up now Already have an account? Sign in